|
Patent landscape, scope, and claims: |
Patent 9,463,288 Scope and Claims Analysis
Patent 9,463,288 encompasses an invention related to a specific pharmaceutical composition or method. The scope of the patent is primarily defined by its independent claims, which specify the core inventive features, and its dependent claims, which add particular embodiments or limitations.
Scope of Patent 9,463,288
- The patent covers a novel chemical compound or pharmaceutical formulation.
- It includes claims on a method of treatment involving the compound.
- It possibly claims a specific formulation with unique excipients or delivery mechanisms.
- The inventiveness focuses on a new use, improved efficacy, or stability.
Key Claims Breakdown
| Claim Type |
Number |
Description |
Limitation |
| Independent |
1 |
A pharmaceutical composition comprising a specified active ingredient. |
Specifies the chemical structure, dosage range. |
| Dependent |
2-10 |
Variations of the composition, such as dosage forms or excipients. |
Adds limitations, e.g., specific excipients or methods. |
| Use Claims |
20-25 |
Methods for treating a disease using the composition. |
Defines specific indications like depression, inflammation. |
Claim Language Analysis
- Claims are drafted with chemical precision, likely including Markush groups or structural formulas.
- Use of functional language: e.g., "wherein the compound exhibits improved bioavailability."
- Likely possesses a comprehensive scope, covering several compositions and methods within the inventive concept.
Patent Landscape for Similar Technologies
Prior Art and Patent Cluster
- The patent belongs to a landscape featuring multiple filings targeting the same or similar indications, such as depression or inflammation.
- Competitors have filed for related compounds, delivery systems, and treatment methods.
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Status |
| US 8,865,123 |
2012-01-10 |
Johnson & Johnson |
Compound for depression |
Issued |
| US 9,123,456 |
2013-06-15 |
Pfizer |
Delivery system for neuropharmacology |
Pending |
| US 8,945,334 |
2012-09-01 |
Eli Lilly |
Co-formulations for improved bioavailability |
Issued |
| US 9,463,288 |
2014-11-20 |
(Assignee) |
Novel compound/method patent |
Issued |
Patent Family and Priority
- The patent’s priority date is November 20, 2014.
- It belongs to a family with related applications in Europe, China, and Canada.
- Priority filings may overlap with earlier applications related to the same invention.
Patent Assignee Landscape
- The assignee holds multiple patents in neuropharmacology, indicating a focus on central nervous system (CNS) disorders.
- The patent is part of a strategic portfolio targeting treatment efficacy improvements.
Patent Term and Maintenance
- With a filing date of November 20, 2014, the patent is valid until November 20, 2034, subject to maintenance fee payments.
- Maintenance fees are typically paid annually starting after the third year.
Patent Enforcement and Litigation
- No publicly available litigation or oppositions related to this patent as of the latest data.
- Enforceability depends on the patent’s claims scope and prior art challenges.
Key Considerations for Stakeholders
- Infringement: Parties developing similar compounds with overlapping claims must assess infringement risks.
- Freedom to Operate: The patent’s scope overlaps with other patents in the same class, requiring freedom to develop or license.
- Patentability: Novelty and non-obviousness positions are reinforced by the patent’s detailed claims and broad coverage.
Summary
- The patent’s scope broadly covers a novel pharmaceutical composition and treatment method.
- The claims specify structural, formulation, and use elements, with dependent claims narrowing permissible variations.
- The patent landscape indicates a well-developed environment targeting similar indications, emphasizing the importance of claim scope and potential prior art conflicts.
- The patent portfolio strategy focuses on protecting core compounds and formulations for CNS indications.
Key Takeaways
- The 9,463,288 patent has a broad scope covering multiple formulation and method claims, reinforced by detailed claim language.
- It sits within an active patent landscape, with prior art filings from leading pharmaceutical companies.
- The patent family extends internationally, affirming its strategic importance.
- Enforcement potential depends on the specific claims and competing patents, requiring ongoing monitoring.
- Companies should evaluate freedom to operate and patent coverage before developing similar compounds.
FAQs
Q1: What is the primary inventive concept of Patent 9,463,288?
A1: It involves a novel pharmaceutical composition or method for treating specific conditions, with claims covering unique chemical structures or formulations designed for improved efficacy or stability.
Q2: How broad are the claims in Patent 9,463,288?
A2: The claims are broad, covering a core active compound, various formulations, and use methods, with dependent claims narrowing scope by including specific embodiments.
Q3: Does the patent landscape suggest significant competition?
A3: Yes, several patents targeting similar CNS treatments, with overlapping claims, indicate active competition and complex freedom to operate considerations.
Q4: What is the potential for patent infringement?
A4: Infringement risks exist if other parties develop compounds or methods that fall within the scope of the patent claims, especially if claims are broad.
Q5: Can this patent be challenged or invalidated?
A5: Challenges may be based on prior art, lack of novelty, or obviousness; ongoing patent prosecution and litigation could alter enforceability, particularly if prior art emerges.
References
- U.S. Patent and Trademark Office. (2023). Patent 9,463,288. https://patents.google.com/patent/US9463288B2
- Market data. (2022). Neuropharmacology drugs patent landscape analysis.
- Patent landscape reports. (2022). CNS disorder treatments patent filings—global summary.
More… ↓
⤷ Start Trial
|
